Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Structure-based optimization of potent PDK1 inhibitorsMauro Angiolini, Patrizia Banfi, Elena Casale, et al.Experimental Cell Research|December 9, 2014
Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancersMichele Modugno, Patrizia Banfi, Fabio Gasparri, et al.Bioorganic & Medicinal Chemistry Letters|May 22, 2012
Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonistsHeidi L Perez, Patrizia Banfi, Jay Bertrand, et al.Bioorganic & Medicinal Chemistry Letters|May 22, 2012
Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonistsGretchen M Schroeder, Donna Wei, Patrizia Banfi, et al.Journal of the National Cancer Institute|November 14, 2015
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, et al.Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.Journal of Medicinal Chemistry|March 23, 2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorMaria Menichincheri, Elena Ardini, Paola Magnaghi, et al.Pageof 1